Nature Communications (Nov 2018)
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
- Marta Compte,
- Seandean Lykke Harwood,
- Ines G. Muñoz,
- Rocio Navarro,
- Manuela Zonca,
- Gema Perez-Chacon,
- Ainhoa Erce-Llamazares,
- Nekane Merino,
- Antonio Tapia-Galisteo,
- Angel M. Cuesta,
- Kasper Mikkelsen,
- Eduardo Caleiras,
- Natalia Nuñez-Prado,
- M. Angela Aznar,
- Simon Lykkemark,
- Jorge Martínez-Torrecuadrada,
- Ignacio Melero,
- Francisco J. Blanco,
- Jorge Bernardino de la Serna,
- Juan M. Zapata,
- Laura Sanz,
- Luis Alvarez-Vallina
Affiliations
- Marta Compte
- Department of Antibody Engineering, Leadartis SL
- Seandean Lykke Harwood
- Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University
- Ines G. Muñoz
- Crystallography and Protein Engineering Unit, Spanish National Cancer Research Centre (CNIO)
- Rocio Navarro
- Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda
- Manuela Zonca
- Department of Antibody Engineering, Leadartis SL
- Gema Perez-Chacon
- Instituto de Investigaciones Biomédicas Alberto Sols (IIBm), CSIC-UAM
- Ainhoa Erce-Llamazares
- Department of Antibody Engineering, Leadartis SL
- Nekane Merino
- Structural Biology Unit, CIC bioGUNE, Parque Tecnológico de Bizkaia
- Antonio Tapia-Galisteo
- Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda
- Angel M. Cuesta
- Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda
- Kasper Mikkelsen
- Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University
- Eduardo Caleiras
- Histopathology Unit, Spanish National Cancer Research Centre (CNIO)
- Natalia Nuñez-Prado
- Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda
- M. Angela Aznar
- Department of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra
- Simon Lykkemark
- Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University
- Jorge Martínez-Torrecuadrada
- Crystallography and Protein Engineering Unit, Spanish National Cancer Research Centre (CNIO)
- Ignacio Melero
- Department of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra
- Francisco J. Blanco
- Structural Biology Unit, CIC bioGUNE, Parque Tecnológico de Bizkaia
- Jorge Bernardino de la Serna
- Central Laser Facility, Science and Technology Facilities Council, Rutherford Appleton Laboratory, Research Complex at Harwell
- Juan M. Zapata
- Instituto de Investigaciones Biomédicas Alberto Sols (IIBm), CSIC-UAM
- Laura Sanz
- Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda
- Luis Alvarez-Vallina
- Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University
- DOI
- https://doi.org/10.1038/s41467-018-07195-w
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Cancer therapy using systemically administrated 4-1BB-targeting antibodies is often associated with severe toxicity due to the nonspecific activation of autoreactive T cells. Here, the authors have developed a trimeric antibody targeting both 4-1BB and EGFR, which activates T cells effectively and shows negligible cytotoxicity.
